Connect with us
Our website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.


Scott+Scott Attorneys at Law LLP Alerts Investors to Securities Class Action Against Geron Corporation (GERN)


Scott+Scott Attorneys at Law LLP (Scott+Scott), a national securities and consumer rights litigation firm, is notifying investors that a class action lawsuit has been filed against Geron Corporation (Geron or the Company) (NASDAQ: GERN), and the Companys President and CEO, related to alleged violations of federal securities laws. If you purchased Geron securities between March 19, 2018 and September 26, 2018, inclusive, you are encouraged to contact Scott+Scott attorney Joe Pettigrew for additional information at (844) 818-6982 or

Geron is a biopharmaceutical company. During the relevant time period, Gerons sole product candidate was imetelstat, a drug intended to treat certain cancers that occur in bone marrow. The IMbark study was designed to ascertain whether imetelstat helped patients with a cancer called myelofibrosis. Geron was developing imetelstat in partnership with Janssen Biotech, Inc. (Janssen), a division of Johnson & Johnson.

The lawsuit alleges that the defendants: (1) misled investors about the results of the IMbark clinical drug study of imetelstat; and (2) as a result, defendants statements about Gerons business, operations, and prospects were materially false and misleading and lacked a reasonable basis at all relevant times.

After making a number of positive statements about imetelstat, the Company issued a press release on September 27, 2018, with disappointing news. The press release indicated that patients in the IMbark study showed only a 10% decrease in spleen volume, when 35% or more was required for success, and a 32% reduction in Total Symptom Score, when at least 50% was needed. The Company also announced that Janssen had terminated its partnership with Geron for the development of imetelstat.

On that news, the price of Geron stock fell $3.92 per share, nearly 63%, from $6.23 per share to $2.31 per share on September 27, 2018.

What You Can Do

If you purchased Geron securities between March 19, 2018 and September 26, 2018, inclusive, or if you have questions about this notice or your legal rights, you are encouraged to contact attorney Joe Pettigrew at (844) 818-6982 or The deadline for lead plaintiff motions is March 23, 2020.

About Scott+Scott Attorneys at Law LLP

Scott+Scott has significant experience in prosecuting major securities, antitrust, and employee retirement plan actions throughout the United States. The firm represents pension funds, foundations, individuals, and other entities worldwide with offices in New York, London, Connecticut, California, and Ohio.

Attorney Advertising

Joe Pettigrew

Scott+Scott Attorneys at Law LLP

230 Park Avenue, 17th Floor, New York, NY 10169-1820

(844) 818-6982

Editorial & Advertiser disclosure

Call for Entries

Global Banking and Finance Review Awards Nominations 2022
2022 Awards now open. Click Here to Nominate

Newsletters with Secrets & Analysis. Subscribe Now


Global Banking & Finance Review® is a leading financial portal and Print Magazine offering News, Analysis, Opinion, Reviews, Interviews & Videos from the world of Banking, Finance, Business, Trading, Technology, Investing, Brokerage, Foreign Exchange, Tax & Legal, Islamic Finance, Asset & Wealth Management. Copyright © 2010-2021 GBAF Publications Ltd - All Rights Reserved.